Cytek (CTKB) Q4 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy CTKB?
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTKB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTKB
Wall Street analysts forecast CTKB stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.430
Low
5.00
Averages
6.17
High
7.50
Current: 4.430
Low
5.00
Averages
6.17
High
7.50
About CTKB
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cytek (CTKB) Q4 2025 Earnings Call Transcript
See More
Cytek Biosciences Reports Record Q4 2025 Revenue and Growth Outlook
- Significant Revenue Growth: Cytek reported fourth-quarter revenue of $62.1 million for 2025, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history, indicating strong performance in the Asia-Pacific and European markets.
- New Product Drive: The newly launched Cytek Aurora Evo system achieved a 21% unit growth in the fourth quarter, boosting sales in the overall Aurora category, demonstrating the company's success in innovative product offerings.
- Sustained Recurring Revenue: In 2025, recurring revenue accounted for 34% of total revenue, growing 21% year-over-year, reflecting the company's ongoing efforts to stabilize its customer base and services, enhancing revenue predictability for the future.
- Optimistic 2026 Outlook: The company anticipates revenue between $205 million and $212 million for 2026, based on improvements in the EMEA and U.S. markets and continued growth in the Asia-Pacific region, showcasing management's confidence in the future market environment.
See More
Cytek Biosciences Q4 Earnings Report Analysis
- Earnings Miss: Cytek Biosciences reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.30, indicating challenges in profitability that could impact investor confidence.
- Revenue Beat: Despite the earnings miss, the company achieved revenue of $62.1 million, exceeding estimates by $3.3 million, suggesting that Cytek maintains a competitive edge in sales, potentially laying the groundwork for future growth.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, capturing investor interest, which may create opportunities for future financing and partnerships, thereby enhancing market trust.
- Historical Financial Context: Cytek's historical financial data provides a backdrop for analyzing its long-term performance; although the current earnings report is disappointing, past data may indicate potential recovery and growth prospects.
See More
Cytek Biosciences (CTKB) Projects $201 Million Revenue for 2025 with Q4 Growth of 8%
- Full Year Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, indicating sustained growth potential in the biosciences sector and reflecting strong market demand.
- Q4 Performance: The company projects fourth-quarter revenue of about $62 million for 2025, representing an 8% increase compared to Q4 2024, demonstrating its competitive strength in the market for products and services.
- Earnings Report Plans: Cytek plans to report its fourth-quarter financial results and provide 2026 guidance during an earnings call expected at the end of February 2026, highlighting its commitment to transparency and investor communication.
- Stock Price Reaction: Cytek Biosciences shares rose 9.7% in pre-market trading on Nasdaq, reaching $5.98, reflecting positive market sentiment regarding its earnings outlook.
See More
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotechnology sector.
- Significant Quarterly Growth: The expected revenue for Q4 2025 is approximately $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services and reagents.
- Regional Market Recovery: Cytek's instrument sales in the EMEA region returned to positive growth in Q4, demonstrating the company's ability to recover in global markets and further solidifying its position internationally.
- Positive Future Outlook: The company plans to provide 2026 financial guidance during its earnings call expected at the end of February 2026, indicating confidence in sustainable growth and profitability, particularly in the potential of the flow cytometry market.
See More
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Expectation: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotech sector.
- Q4 Growth: The expected revenue for Q4 2025 is around $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services, reagents, and instrument sales in the Asia-Pacific region.
- Positive Market Trends: CEO Wenbin Jiang noted that the revenue growth in Q4 reflects a positive rebound in instrument sales in the EMEA region, indicating the company's potential for sustainable growth in the global flow cytometry market.
- Future Outlook: Cytek plans to report its financial results for 2025 and provide guidance for 2026 during its earnings call expected at the end of February 2026, demonstrating confidence in future growth and strategic planning.
See More
Cytek (CTKB) Q4 2025 Earnings Call Transcript
See More
Cytek Biosciences Reports Record Q4 2025 Revenue and Growth Outlook
- Significant Revenue Growth: Cytek reported fourth-quarter revenue of $62.1 million for 2025, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history, indicating strong performance in the Asia-Pacific and European markets.
- New Product Drive: The newly launched Cytek Aurora Evo system achieved a 21% unit growth in the fourth quarter, boosting sales in the overall Aurora category, demonstrating the company's success in innovative product offerings.
- Sustained Recurring Revenue: In 2025, recurring revenue accounted for 34% of total revenue, growing 21% year-over-year, reflecting the company's ongoing efforts to stabilize its customer base and services, enhancing revenue predictability for the future.
- Optimistic 2026 Outlook: The company anticipates revenue between $205 million and $212 million for 2026, based on improvements in the EMEA and U.S. markets and continued growth in the Asia-Pacific region, showcasing management's confidence in the future market environment.
See More
Cytek Biosciences Q4 Earnings Report Analysis
- Earnings Miss: Cytek Biosciences reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.30, indicating challenges in profitability that could impact investor confidence.
- Revenue Beat: Despite the earnings miss, the company achieved revenue of $62.1 million, exceeding estimates by $3.3 million, suggesting that Cytek maintains a competitive edge in sales, potentially laying the groundwork for future growth.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, capturing investor interest, which may create opportunities for future financing and partnerships, thereby enhancing market trust.
- Historical Financial Context: Cytek's historical financial data provides a backdrop for analyzing its long-term performance; although the current earnings report is disappointing, past data may indicate potential recovery and growth prospects.
See More
Cytek Biosciences (CTKB) Projects $201 Million Revenue for 2025 with Q4 Growth of 8%
- Full Year Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, indicating sustained growth potential in the biosciences sector and reflecting strong market demand.
- Q4 Performance: The company projects fourth-quarter revenue of about $62 million for 2025, representing an 8% increase compared to Q4 2024, demonstrating its competitive strength in the market for products and services.
- Earnings Report Plans: Cytek plans to report its fourth-quarter financial results and provide 2026 guidance during an earnings call expected at the end of February 2026, highlighting its commitment to transparency and investor communication.
- Stock Price Reaction: Cytek Biosciences shares rose 9.7% in pre-market trading on Nasdaq, reaching $5.98, reflecting positive market sentiment regarding its earnings outlook.
See More
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotechnology sector.
- Significant Quarterly Growth: The expected revenue for Q4 2025 is approximately $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services and reagents.
- Regional Market Recovery: Cytek's instrument sales in the EMEA region returned to positive growth in Q4, demonstrating the company's ability to recover in global markets and further solidifying its position internationally.
- Positive Future Outlook: The company plans to provide 2026 financial guidance during its earnings call expected at the end of February 2026, indicating confidence in sustainable growth and profitability, particularly in the potential of the flow cytometry market.
See More
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Expectation: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotech sector.
- Q4 Growth: The expected revenue for Q4 2025 is around $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services, reagents, and instrument sales in the Asia-Pacific region.
- Positive Market Trends: CEO Wenbin Jiang noted that the revenue growth in Q4 reflects a positive rebound in instrument sales in the EMEA region, indicating the company's potential for sustainable growth in the global flow cytometry market.
- Future Outlook: Cytek plans to report its financial results for 2025 and provide guidance for 2026 during its earnings call expected at the end of February 2026, demonstrating confidence in future growth and strategic planning.
See More
